Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
V419963-5mg | 5mg | In stock | $88.90 | |
V419963-10mg | 10mg | In stock | $147.90 | |
V419963-25mg | 25mg | In stock | $276.90 | |
V419963-50mg | 50mg | In stock | $444.90 | |
V419963-100mg | 100mg | In stock | $741.90 |
Synonyms | Vodobatinib | 1388803-90-4 | SCO-088 | K0706 | K-0706 | Vodobatinib [USAN] | N8Q12KU2SW | Vodobatinib (USAN) | 2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide | 2-Chloro-6-methyl-N'-(4-methyl-3-(quinolin-3-ylethynyl)benzoyl)benzohydrazide | 4- |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of ABL proto-oncogene 1; non-receptor tyrosine kinase |
Product Description | Product description: Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research |
ALogP | 6 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 2-chloro-6-methyl-N'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide |
---|---|
INCHI | InChI=1S/C27H20ClN3O2/c1-17-10-12-22(26(32)30-31-27(33)25-18(2)6-5-8-23(25)28)15-20(17)13-11-19-14-21-7-3-4-9-24(21)29-16-19/h3-10,12,14-16H,1-2H3,(H,30,32)(H,31,33) |
InChi Key | ZQOBVMHBVWNVBG-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3 |
Isomeric SMILES | CC1=C(C(=CC=C1)Cl)C(=O)NNC(=O)C2=CC(=C(C=C2)C)C#CC3=CC4=CC=CC=C4N=C3 |
PubChem CID | 89884852 |
Molecular Weight | 453.9 |
PubChem CID | 89884852 |
---|---|
ChEMBL Ligand | CHEMBL4130229 |
CAS Registry No. | 1388803-90-4 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2203354 | Certificate of Analysis | Jun 07, 2022 | V419963 |
G2203355 | Certificate of Analysis | Jun 07, 2022 | V419963 |
G2203356 | Certificate of Analysis | Jun 07, 2022 | V419963 |
G2203357 | Certificate of Analysis | Jun 07, 2022 | V419963 |
G2203358 | Certificate of Analysis | Jun 07, 2022 | V419963 |
Solubility | DMSO : 125 mg/mL (275.38 mM; Need ultrasonic) |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation |
Precautionary Statements | P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P264:Wash hands [and …] thoroughly after handling. P337+P313:IF eye irritation persists: Get medical advice/attention. P362+P364:Take off contaminated clothing and wash it before reuse. P332+P313:IF SKIN irritation occurs: Get medical advice/attention. |
1. Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, O'Hare T. (2019) BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.. Exp Hematol, 77 (3): (36-40.e2). [PMID:31493432] |